LONDON – Newco Valo Therapeutics Ltd. has spun out of Helsinki University, Finland, with €3 million (US$3.2 million) of a first tranche of seed funding to commercialize next-generation peptide-coated oncolytic viruses that promote a specific antitumor immune activation.